Subunit vaccines have been identified by the National Institutes of Allergy and Infectious Disease as the safest form of a vaccine available to the general population. Formulation of a subunit vaccine employing a particle based system based on acetalated dextran have already been demonstrated and continue to be under evaluation in several areas. As a platform, Ac-DEX is quickly being recognized for having numerous technical advantages over traditional subunit formulations. First, Ac-Dex particles have been shown to stabilize proteins and retain functional activity outside the cold chain - unlike mainstream vaccines. Second, Ac-DEX formulations facilitate needle-free vaccine delivery and increased potential for patient acceptance. Thus, is in anticipated that vaccines based on acetalated dextran will have an industry-wide impact and shape the way in which modern vaccine formulations are delivered.